Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

• Status: Completed
• Trial end date: 2018-05-31
• Target enrollment: 0
• Participant gender: Female

Summary

This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D&E procedure, but doctors want to clarify how digoxin effects D&E procedure time, if at all.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: FPA Women's Health; FPA Women’s Health; Oregon Health and Science University; Society of Family Planning
• Treatments: Digoxin

Criteria

Inclusion Criteria:

• 20 weeks 0 days-24 weeks 0 days gestation

• English or Spanish speaking

• 18 years or older

Exclusion Criteria:

• Under 18

• Contraindications to digoxin